Oral Abstract Session

 
 
Kai-Keen Shiu, Thierry Andre, Tae Won Kim, et al.
 
The authors conclude:    
Pembro provided a statistically significant improvement in PFS vs chemo as first-line therapy for patients with MSI-H/dMMR mCRC, with fewer TRAEs observed. Furthermore, pembro provided a clinically meaningful improvement in PFS2 for patients with MSI-H/dMMR mCRC.
 
 
Tenna V Henriksen, Noelia Tarazona, Thomas Reinert, et al.
 
The authors conclude:    
Postoperative ctDNA positive status was associated with markedly reduced RFS compared to CEA. The study also shows that effective therapy can be curative in a portion of MRD-positive patients. In a longitudinal setting, ctDNA analysis predicted the risk of recurrence and is a more reliable biomarker for treatment response monitoring.
 
The authors conclude:    
Pembrolizumab added to chemoRT as part of TNT was safe and without unexpected short-term toxicities but failed to improve the NAR score. The secondary endpoints including PFS and OS have not been reached. Correlative analysis for both T-cell and myeloid cell populations in the tissue and blood in addition to comprehensive cytokine analysis is ongoing. NCT02921256. Support: U10CA180868, -180822; UG1-189867; U24-196067.
 
 
Thierry Andre, Dominique Berton, Giuseppe Curigliano, et al.
 
The authors conclude:    
Dostarlimab demonstrated durable antitumor activity in a cohort of dMMR solid tumor pts, the majority of whom had GI cancers. The safety profile was consistent with other cohorts in GARNET, with immune-related TRAEs infrequent and low grade.
 

Rapid Abstract Session

 
 
Romain Cohen, Qian Shi, Jeffrey P. Meyers, et al.
 
The authors conclude:   

TD are found in more than one fourth of stage III colon cancer specimens. The number of TD has a linear deleterious effect on patients’ prognosis. Adding the number of TD to the count of lymph node metastases improves the prognostication accuracy of the TNM staging. Support: U10CA180821, U10CA180882; https://acknowledgments.alliancefound.org.

 
Michael S. Lee, Patrick J. Loehrer Sr., Iman Imanirad, et al.
 
The authors conclude:    

The combination of panitumumab, ipilimumab, and nivolumab demonstrated evidence of activity and met its prespecified primary endpoint of 12-wk response rate criteria to merit further study. The PFS in this single-arm study compares favorably to expected PFS for anti-EGFR monotherapy in RAS wild-type patients, and results suggest activity of immune checkpoint inhibitors combined with anti-EGFR therapy in MSS mCRC.

 
Arthur Sun Myint, Brice Thamphya, Jean-Pierre Gerard
 
The authors conclude:    
Non-TME surgical treatment for cT2-cT3a-b rectal cancer is feasible in those who are fit and wish to avoid surgery (Watch & Wait). Those who needed surgery can be offered salvage surgery immediately for local residual disease or for local regrowth at a later date. Organ preservation of 80.5% (blinded) can be achieved without compromising their chance of cure.
 
 
Douglas S. Swords, Hop S. Tran Cao, Brian K. Bednarski, et al.
 
The authors conclude:    
Treatment disparities mediate at least 20-30% of OS disparities in NHBs and NHWs with stage IV CRC. These estimates may represent the lower bound of true PMs since many aspects of treatment quality were unmeasured. These findings imply that policies addressing treatment disparities are projected to partially close survival gaps.
 
 
Eric Van Cutsem, Iwona Danielewicz, Mark P. Saunders, et al.
 
The authors conclude:    
Our study demonstrated earlier a median PFS of 9.2 months for TT-B and 7.8 months for C-B when administered to patients with previously untreated unresectable mCRC ineligible for standard combination chemotherapy. The final study analysis performed on OS, the main secondary endpoint, provided further evidence for TT-B as a noteworthy valuable regimen in this population settings.
 
 
Valerie Boige, Eric FRANCOIS, Meher BEN Abdelghani, et al.
 
The authors conclude:    
Based on the study hypothesis, the cetuximab maintenance arm did not meet the primary objective. However, the clinically meaningful difference in PFS without any overlap in the confidence intervals between the two arms warrants further investigation.